memantine + memantine + placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Aphasia
Conditions
Aphasia, Stroke
Trial Timeline
Mar 1, 2005 → Nov 1, 2007
NCT ID
NCT00640198About memantine + memantine + placebo
memantine + memantine + placebo is a approved stage product being developed by Lundbeck for Aphasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00640198. Target conditions include Aphasia, Stroke.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00640198 | Approved | Completed |
Competing Products
3 competing products in Aphasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Wait first, then levetiracetam + Levetiracetam first, then wait | UCB | Phase 1 | 30 |
| memantine | Lundbeck | Approved | 82 |
| Neflamapimod + Placebo | CervoMed | Phase 2 | 44 |